# A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

> **NCT03145831** · PHASE3 · TERMINATED · sponsor: **Versartis Inc.** · enrollment: 21 (actual)

## Conditions studied

- Growth Hormone Deficiency

## Interventions

- **DRUG:** Somavaratan

## Key facts

- **NCT ID:** NCT03145831
- **Lead sponsor:** Versartis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-31
- **Primary completion:** 2017-11-30
- **Final completion:** 2017-11-30
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not achieved
- **Last updated:** 2018-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03145831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03145831, "A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03145831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*